scholarly journals Additional possibilities of antihypertensive therapy for metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 41-46
Author(s):  
O A Kislyak ◽  
M V Pokhilchenko
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Receptor Blockers ◽  
Fixed Dose ◽  
Angiotensin Receptor ◽  
Metabolic Disturbances ◽  
First Choice ◽  
Receptor Blockers ◽  
Dose Combination ◽  
Symptom Complex

Metabolic syndrome (MS) is a clinical and laboratory symptom complex that encompasses abdominal obesity, carbohydrate and fat metabolic disturbances, arterial hypertension (AH), and target organ involvement. The drugs of first choice in the management of patients with AH and MS are renin-angiotensin-aldosterone system (RAAS) inhibitors, angiotensin receptor blockers (ARB) in particular, when combined with calcium antagonists (CA), which have been proven to be metabolically neutral and able to reduce the risk of type 2 diabetes mellitus. A fixed-dose combination of the ARB losartan and the CA amlodipine has additional capabilities to affect the components of MS due to higher adiponectin and lower uric acid levels.

Comparison of medication adherence between fixed-dose combination of angiotensin receptor blockers and statin and free-combination therapy

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J.H Choi ◽  
J.M Choi ◽  
Y.J Jang ◽  
M Kang ◽  
S.H Lee
Keyword(s):  
Medication Adherence ◽  
Angiotensin Receptor Blockers ◽  
Female Gender ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Angiotensin Receptor ◽  
Real World Data ◽  
Persistence Rate ◽  
Receptor Blockers ◽  
Dose Combination

Abstract Background Non-adherence to angiotensin receptor blockers (ARB) or statin is one of major reasons of insufficient treatment for patients with hyperlipidemia and hypertension. We investigated whether fixed-dose combination (FDC) of ARB and statin improved adherence compared to traditional free combination (FC). Methods In this retrospective nationwide cohort study, adherence of 128,369 patients who started ARB and stain including atorvastatin or rosuvastatin between July 2014 and June 2015 was investigated. Primary endpoint was proportion of days covered (PDC) per 180 days up to day 540. Good compliance defined by PDC≥80% and persistency rate defined by patients remaining on medication were also investigated. Results Patients were 62.9 years of mean age with 48.2% female gender. Compared to FC (N=90,759, 70.7%), FDC (N=37,610, 29.3%) showed higher PDC at day 180 (86% vs 70%), 360 (77% vs 62%), and 540 (74% vs 55%, p<0.001, all). Frequency of patients with PDC≥80% was also higher in FDC compared to FC at day 180 (80.1% vs 51.8%), 360 (71.7% vs 54.2%), and 540 (69.2% vs 49.3%, p<0.001, all). Persistency rate at day 540 was higher in FDC compared to FC (50.4% vs 27.3%, p<0.001). The mean decline in PDC per 180 days were significantly lower in FDC compared to FC per 180 days (6.0% vs. 7.5%, p<0.001). Conclusions In this real-world data analysis, FDC resulted in higher medication adherence and persistence compared to FC among patients who started both ARB and atorvastatin or rosuvastatin. Persistence rate btw FDC and FC Funding Acknowledgement Type of funding source: None

scholarly journals ROADMAP and ORIENTAL Trials: The Re-emergence of J-Curve Ghost?

2011 ◽  
Vol 2 ◽  
pp. JCM.S7521 ◽  
Author(s):  
Yoshiyuki Hamamoto ◽  
Hiroyuki Koshiyama
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Events ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
J Curve ◽  
Pressure Lowering ◽  
Risk Patients ◽  
Receptor Blockers

It still remains unknown whether angiotensin-receptor blockers (ARBs) are cardioprotective in patients with type 2 diabetes. The recent two clinical trials, the ROADMAP and the ORIENT, have suggested that fatal cardiovascular events or cardiovascular deaths were unexpectedly higher in olmesartan group. These results suggest that aggressive blood pressure lowering may cause a higher risk in some high-risk patients, especially in those with preexisting coronary heart disease, indicating a possibility that the J-curve phenomenon may exist in some group of patients.

Sign in / Sign up

Export Citation Format

Share Document